Completed PHASE2 INTERVENTIONAL 3-arm NCT06337981

Efficacy and Safety of AJU-S56 in Dry Eye Syndrome Patients

A Phase 2 Multicenter, Randomized, Double-blinded, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AJU-S56 in Patients With Dry Eye Disease

Sponsor: AJU Pharm Co., Ltd.

Conditions Dry Eye Syndromes

Interventions (AJU-S56 5% and placebo) AJU-S56 5% Placebo(Vehicle)

Updated 5 times since 2024 Last updated: Apr 26, 2024 Started: Nov 22, 2021 Primary completion: Jun 14, 2022 Completion: Nov 28, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Dry Eye Syndromes, this trial is completed. The trial is conducted by AJU Pharm Co., Ltd. and has accumulated 5 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
May 2024 — Jul 2024 [monthly]

Completed PHASE2
Apr 2024 — May 2024 [monthly]

Completed PHASE2

First recorded

Nov 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AJU Pharm Co., Ltd.
GL Pharm Tech Corporation

Data source: AJU Pharm Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea